Zegfrovy Sunvozertinib compound, a quite new therapeutic agent, is generating significant attention within the cancer community. Its mechanism of action mainly involves specific inhibition of skin growth factor receptor (EGFR) protein activity, showing hope in treating various tumor kinds. Early clinical investigations have demonstrated positive re